Telix制药公司采用莱茵制药公司的形式,为前列腺癌开发放射药品RHN001;第一阶段/IIa试验从现场生产开始,供区域无障碍使用。 Telix Pharmaceuticals forms Rhine Pharma to develop radiopharmaceutical RHN001 for prostate cancer; Phase I/IIa trial begins with on-site production for regional accessibility.

Telix制药有限公司已经从莱茵制药公司出发,以增加全球获得用于癌症成像和治疗的新型放射药物的机会。 Telix Pharmaceuticals Limited has spun off Rhine Pharma to enhance global access to innovative radiopharmaceuticals for cancer imaging and treatment. Rhine Pharma 与海德堡大学医院合作成立，正在开发治疗诊断化合物 RHN001，目前正在进入晚期前列腺癌的 I/IIa 期临床研究。 Formed in collaboration with Heidelberg University Hospital, Rhine Pharma is developing the theranostic compound RHN001, now entering a Phase I/IIa clinical study for advanced prostate cancer. 使用锝 99m （99mTc） 和铼 188 （188Re） 可以进行现场生产，使基础设施有限的地区受益。 The use of technetium-99m (99mTc) and rhenium-188 (188Re) allows for on-site production, benefiting regions with limited infrastructure.